STOCK TITAN

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Vir Biotechnology, Inc. (VIR) will announce its first-quarter financial results on May 2, 2024, followed by a conference call. The update will be available on their website. Investors can join the call via webcast or phone.
Positive
  • None.
Negative
  • None.

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.

The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir’s website at https://investors.vir.bio/events-presentations or listen in by dialing the U.S. toll free number (888) 800-8770 or international +1 (646) 307-1953, Conference ID: 756877. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

Media

Carly Scaduto

Senior Director, External Communications

cscaduto@vir.bio

+1 314-368-5189

Investors

Richard Lepke

Senior Director, Investor Relations

rlepke@vir.bio

+1 978-973-9986

Source: Vir Biotechnology, Inc.

FAQ

When will Vir Biotechnology announce its first-quarter financial results?

Vir Biotechnology will announce its first-quarter financial results on May 2, 2024.

How can investors access the corporate update and financial results?

Investors can access the corporate update and financial results on the Press Releases section of Vir's website at www.vir.bio.

How can participants join the conference call?

Participants can join the conference call via webcast on the Events & Presentations page of Vir's website or by dialing the U.S. toll-free number (888) 800-8770 or international +1 (646) 307-1953, Conference ID: 756877.

Will a recorded version of the conference call be available?

Yes, a recorded version of the call will be available on the website approximately two hours after the event and will be archived for 30 days.

Vir Biotechnology, Inc.

NASDAQ:VIR

VIR Rankings

VIR Latest News

VIR Stock Data

1.02B
117.08M
11.9%
74.31%
4.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN FRANCISCO